Hope S. Rugo
Member of Scientific Advisory BoardDr. Hope S. Rugo, M.D., FASCO, Ph.D., is Member of Clinical Advisory Board of Hexagon Bio, Inc. from May 2026. She was Independent Director of Dignitana AB (publ) from May 23, 2024 until June 5, 2025. Dr. Rugo was Member of Scientific Advisory Board at Totus Medicines Inc. until July 2025. She serves as Member of Scientific Advisory Board at Sardona Therapeutics, Inc. She serves as Member of serves as Member of Breast Cancer Clinical Advisory Board of Anixa Biosciences, Inc. since February 2023. She is a leader and specialist in breast cancer research and recipient of numerous awards. She is Co-Chair of the Triple Negative Working Group, a Member of the Translational Breast Cancer Research Consortium (TBCRC) and Alliance Breast Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB). She serves as Scientific Advisory Board at CytoDyn Inc. since September 2020. Dr. Rugo is a Clinical Professor of Medicine in the Division of Hematology and Oncology and Breast Oncology Clinical Trials Education Program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She serves as Member of Sceintific Advisory Board at SynDevRx, Inc. since 2020. Dr. Rugo had been a Member of Scientific Advisory Board at Syndax Pharmaceuticals, Inc. since July 2016. She has been a Member of Medical Oncology Advisory Board at Bioasis Technologies Inc. since December 2019. She served as a Member of Scientific & Medical Advisory Board at Galena Biopharma, Inc. since March 21, 2012. She served as Member of Scientific & Medical Advisory Board at Antigen Express, Inc. since May 15, 2012. She is also an investigator in the Bay Area Spore at UCSF's Carol Franc Buck Breast Cancer Center and the Principal investigator of a number of clinical trials testing new treatment approaches. Dr. Rugo is the Principal investigator of multiple clinical trials researching novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity and the evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy and supportive care. Dr. Rugo is an investigator and novel agent chaperone for ISPY2, an innovative multicenter neoadjuvant chemotherapy trial. She has published many peer-reviewed papers and has given presentations on a variety of cancer-related topics and is the breast section editor for Cancer.Net, a patient focused publication of the American Society of Clinical Oncology. She is one of three recipients of a Komen Promise Award and received the Cancer Care Physician of the Year Award in 2010. After graduating summa cum laude from Tufts University, Dr. Rugo received her M.D. from the University of Pennsylvania and completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. She also completed a few-year postdoctoral fellowship in immunology at Stanford University.
Positions
- Company NameCytoDyn Inc.Stock CodeCYDYPositionMember of Scientific Advisory BoardColleagues
- RERobert E. HoffmanCEO & Principal Accounting Officer
- TDTanya Durkee UrbachIndependent Chairman of the Board
- TBTyler BlokChief Legal Officer & Corporate Secretary
- JPJacob P. LalezariHead of Research and Translational Sciences
- LWLauren WilcoxenCOO & Head of Regulatory Affairs
- RMRyan M. DunlapIndependent Director
- SMStephen M. SimesIndependent Director
- JBJonah B. SachaMember of Scientific Advisory Board
